HNRNPA1 and neoplasm: In vivo, xenograft tumor models, both HNRNPA1 knockout and selective inhibition of K350 lactylation led to a substantial decrease in tumor growth, as evidenced by reduced tumor weight and volume (Fig. 4H–J).